abstract：:Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

journal_title：Drugs

authors： Markham A

更新日期：2016-07-01 00:00:00

abstract：:Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...

journal_title：Drugs

authors： Burness CB,Scott LJ

更新日期：2016-05-01 00:00:00

abstract：:Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1 or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) signalling pathway leaves patients with TSC susceptible to the growth of non-malignant tumours in multiple organs. Previously, surgery was t...

journal_title：Drugs

authors： Curatolo P,Bjørnvold M,Dill PE,Ferreira JC,Feucht M,Hertzberg C,Jansen A,Jóźwiak S,Kingswood JC,Kotulska K,Macaya A,Moavero R,Nabbout R,Zonnenberg BA

更新日期：2016-04-01 00:00:00

abstract：:A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

journal_title：Drugs

authors： Keating GM

更新日期：2016-04-01 00:00:00

abstract：:The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

journal_title：Drugs

authors： Seiler T,Hutter G,Dreyling M

更新日期：2016-04-01 00:00:00

abstract：:Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...

journal_title：Drugs

authors： Blair HA,Keating GM

更新日期：2016-03-01 00:00:00

abstract：:A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficac...

journal_title：Drugs

authors： Pleasants RA,Wang T,Gao J,Tang H,Donohue JF

更新日期：2016-03-01 00:00:00

abstract：:Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

journal_title：Drugs

authors： Trendowski M

更新日期：2015-11-01 00:00:00

abstract：:As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...

journal_title：Drugs

authors： Longoria TC,Tewari KS

更新日期：2015-11-01 00:00:00

abstract：:A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

journal_title：Drugs

authors： Hoy SM

更新日期：2015-10-01 00:00:00

abstract：:Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

journal_title：Drugs

authors： Greig SL

更新日期：2015-09-01 00:00:00

abstract：:Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empaglifl...

journal_title：Drugs

authors： Kim ES,Deeks ED

更新日期：2015-09-01 00:00:00

abstract：:Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic car...

journal_title：Drugs

authors： Markham A

更新日期：2015-09-01 00:00:00

abstract：:Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a lar...

journal_title：Drugs

authors： De Luca G,Savonitto S,van't Hof AW,Suryapranata H

更新日期：2015-07-01 00:00:00

abstract：:Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...

journal_title：Drugs

authors： Plosker GL

更新日期：2015-07-01 00:00:00

abstract：:Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

journal_title：Drugs

authors： Keating GM

更新日期：2015-07-01 00:00:00

abstract：:Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...

journal_title：Drugs

authors： Syed YY,McCormack PL

更新日期：2015-07-01 00:00:00

abstract：:Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluores...

journal_title：Drugs

authors： Keating GM

更新日期：2015-05-01 00:00:00

abstract：:Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...

journal_title：Drugs

authors： Hoy SM

更新日期：2015-05-01 00:00:00

abstract：:Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

journal_title：Drugs

authors： Garnock-Jones KP

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

journal_title：Drugs

authors： Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

更新日期：2015-04-01 00:00:00

abstract：:Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

journal_title：Drugs

authors： Holtzman CW,Brady KA,Yehia BR

更新日期：2015-04-01 00:00:00

abstract：:The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...

journal_title：Drugs

authors： Tsai KK,Daud AI

更新日期：2015-04-01 00:00:00

abstract：:This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...

journal_title：Drugs

authors： Elshoff JP,Cawello W,Andreas JO,Mathy FX,Braun M

更新日期：2015-04-01 00:00:00

abstract：:Alipogene tiparvovec (Glybera®; AMT-011, AAV1-LPL(S447X)) is an adeno-associated virus serotype 1-based gene therapy for adult patients with familial lipoprotein lipase (LPL) deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. It is administered as a one-time ...

journal_title：Drugs

authors： Scott LJ

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:While a variety of intervention options have been described for pemphigus vulgaris, the optimal treatment strategy has not been established. OBJECTIVES:The objective of this systematic review is to assess the literature on the efficacy and safety of interventions for the treatment of pemphigus vulgaris. DA...

journal_title：Drugs

authors： Zhao CY,Murrell DF

更新日期：2015-02-01 00:00:00

abstract：:Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...

journal_title：Drugs

authors： Roth M

更新日期：2015-01-01 00:00:00

abstract：:Delamanid (Deltyba(®)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for...

journal_title：Drugs

authors： Blair HA,Scott LJ

更新日期：2015-01-01 00:00:00

abstract：:Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

journal_title：Drugs

authors： McKeage K

更新日期：2015-01-01 00:00:00

abstract：:Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conven...

journal_title：Drugs

authors： Dobesh PP,Fanikos J

更新日期：2014-11-01 00:00:00

abstract：:Despite the availability of effective pharmacological treatments to aid the control of blood pressure, the global rate of uncontrolled blood pressure remains high. As such, further measures are required to improve blood pressure control. Recently, several national and international guidelines for the management of hyp...

journal_title：Drugs

authors： Kjeldsen S,Feldman RD,Lisheng L,Mourad JJ,Chiang CE,Zhang W,Wu Z,Li W,Williams B

更新日期：2014-11-01 00:00:00

abstract：:The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are c...

journal_title：Drugs

authors： Fardet L,Fève B

更新日期：2014-10-01 00:00:00

abstract：:Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

journal_title：Drugs

authors： Yang LP

更新日期：2014-10-01 00:00:00

abstract：:In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...

journal_title：Drugs

authors： Mohty M,Bacigalupo A,Saliba F,Zuckermann A,Morelon E,Lebranchu Y

更新日期：2014-09-01 00:00:00

abstract：:Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

journal_title：Drugs

authors： Dhillon S

更新日期：2014-09-01 00:00:00

abstract：:Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are cau...

journal_title：Drugs

authors： Viehman JA,Nguyen MH,Doi Y

更新日期：2014-08-01 00:00:00

abstract：:With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...

journal_title：Drugs

authors： Scott LJ

更新日期：2014-08-01 00:00:00

abstract：:Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

journal_title：Drugs

authors： Deeks ED

更新日期：2014-07-01 00:00:00

abstract：:Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outw...

journal_title：Drugs

authors： Chrusciel P,Rysz J,Banach M

更新日期：2014-06-01 00:00:00

abstract：:Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...

journal_title：Drugs

authors： Plosker GL

更新日期：2014-02-01 00:00:00